[Skip to Content]
[Skip to Content Landing]
May 21, 1982

Intravenous Metoclopramide: An Effective Antiemetic in Cancer Chemotherapy

Author Affiliations

From the Departments of Medicine (Dr Strum) and Pharmacy (Drs McDermed and Riech), Brotman Medical Center, Culver City, Calif; the Hematology-Oncology Medical Group of Orange County, Tustin, Calif (Dr Opfell); the Department of Medicine, Section of Hematology, Los Angeles County-University of Southern California Medical Center, Los Angeles, and the School of Pharmacy, University of Southern California, Los Angeles (Drs McDermed and Riech).

JAMA. 1982;247(19):2683-2686. doi:10.1001/jama.1982.03320440031028

An open-label clinical trial was conducted to test the safety and efficacy of intravenous metoclopramide monohydrochloride in preventing chemotherapy-induced nausea and vomiting. Thirty-eight patients received a total of 83 assessable courses of chemotherapy with cisplatin alone or in combination with other cytotoxic agents. In 19 of 38 patients (50%) or 40 of 83 courses (48%, nausea or vomiting did not occur ("total protection") and in six of 38 patients (16%) or 19 of 83 courses (23%), emesis occurred one or two times ("major protection"). Thus, 25 of 38 patients (66%) receiving 59 of 83 courses (71%) of cisplatin-containing chemotherapy attained either total or major antiemetic protection with metoclopramide. In those patients who received multiple courses of chemotherapy, antiemetic protection afforded by metoclopramide remained unabated. At this dosage, the drug was well tolerated with minimal side effects. Intravenous metoclopramide is consistently effective in preventing emesis associated with cisplatin when used either alone or in combination with other cancer chemotherapy agents that are in themselves emetogenic.

(JAMA 1982;247:2683-2686)